Latest Articles
Pessary Use and Satisfaction in POP Management - Physician's Weekly
Pessary Use and Satisfaction in POP Management Physician's Weekly
Published: Jan. 3, 2025, 11:36 a.m.
Top vitamin deficiencies that can land you in hospital; how to resolve them - MSN
Top vitamin deficiencies that can land you in hospital; how to resolve them MSN
Published: Jan. 2, 2025, 10:09 p.m.
How I Went From Struggling With My Health To Building A Fitness Empire - SheThePeople
How I Went From Struggling With My Health To Building A Fitness Empire SheThePeople
Published: Jan. 2, 2025, 10:09 a.m.
2024? It’s a Wrap! - Femtech Insider
2024? It’s a Wrap! Femtech Insider
Published: Jan. 1, 2025, 2:47 p.m.
The most memorable moments in Wales in 2024 - BBC.com
The most memorable moments in Wales in 2024 BBC.com
Published: Dec. 31, 2024, 1:34 p.m.
Peripheral Blood NLR Predicts LEN/PEM Efficacy in Endometrial Cancer - Physician's Weekly
Peripheral Blood NLR Predicts LEN/PEM Efficacy in Endometrial Cancer Physician's Weekly
Published: Dec. 31, 2024, 12:27 p.m.
Tina Ahuja faces backlash for calling period pain "Not Real," netizens demand awareness - MSN
Tina Ahuja faces backlash for calling period pain "Not Real," netizens demand awareness MSN
Published: Dec. 30, 2024, 7:43 a.m.
Tina Ahuja faces backlash for calling period pain 'Not Real,' netizens demand awareness - TOI Etimes
Tina Ahuja faces backlash for calling period pain 'Not Real,' netizens demand awareness TOI Etimes
Published: Dec. 29, 2024, 7:36 a.m.
Wisp Teams Up with Nourish to Enhance Their GLP-1 Weight Care Services with Nutrition Support - Femtech Insider
Wisp Teams Up with Nourish to Enhance Their GLP-1 Weight Care Services with Nutrition Support Femtech Insider
Published: Dec. 29, 2024, 6:41 a.m.
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for locally advanced uterine cervical cancer, and durvalumab and olaparib for advanced or recurrent endometrial cancer in Japan - springermedicine.com
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for locally advanced uterine cervical cancer, and durvalumab and olaparib for advanced …
Published: Dec. 28, 2024, 12:47 p.m.
Link copied to clipboard!